EUVIMEDOpdag EUVIMED
Multizentrische StudieBeobachtungsstudie

Lung T1‐MRI and Multi‐Breath Washout Detect Longitudinal Changes in Children 6–11 Years Old After Beginning Elexacaftor/Tezacaftor/Ivacaftor (ETI) Therapy

Samya Z Nasr, Chris A Flask iD, Madison E Kretzler iD, James E Slaven, Aparna Joshi, Maryam Ghadimi Mahani, Charles Clem, Matthew Cooper, Susan Farr, Christina J MacAskill, Amit Gupta, Matthew Ferrebee and 2 more

Pediatric Pulmonology · 2026-04 · 61 (4)

DOI: 10.1002/ppul.71628 ↗

At a glance

Multizentrische Studie in Pediatric Pulmonology, published online on 2026-04-20. Written by Samya Z Nasr and 13 co-authors. Institution: Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA. Major MEDLINE topics: Aminophenols, Cystic Fibrosis, Lung, Magnetic Resonance Imaging. 37 references. Funded by: Cystic Fibrosis Foundation, Bethesda, Maryland.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy was approved in 2021 for clinical use in children with CF (cwCF) age 6–11 years, depending on their genetic variants. Our prior multi‐center study showed that lung T1‐MRI and multi‐breath washout (MBW) provided complementary pathobiological information on CF lung disease in cwCF 6–11 years of age. In this study, we hypothesized that lung T1‐MRI and MBW will sensitively detect lung improvements in cwCF after starting ETI therapy. To test this hypothesis, we obtained longitudinal lung T1‐MRI, MBW, and spirometry assessments in a cohort of cwCF 6–11 years of age before and after starting ETI therapy.

Methods

CwCF ( n = 48, mean age = 8.6 years) were recruited from 3 cystic fibrosis (CF) centers (Riley Hospital for Children (Indianapolis, IN), University of Michigan, Michigan Medicine (Ann Arbor, MI), and Rainbow Babies and Children's Hospital (Cleveland, OH) for longitudinal lung T1‐MRI, MBW, and spirometry assessments before initiating ETI (baseline) as well as at 3‐months and 6‐months after initiating ETI. MBW and spirometry were performed according to published guidelines to obtain measurements of the lung clearance index (LCI) and percent predicted forced expiratory volume at 1 s (ppFEV1), and percent predicted forced expiratory flow at 25%–75% (FEF 25 %–75% ), respectively. Lung T1‐MRI was used to obtain assessments of % normal lung perfusion (%NLP). An ANOVA analysis and descriptive statistics were used to compare the longitudinal changes in the lung T1‐MRI, MBW, and spirometry findings.

Results

Across all subjects, significant improvements in both spirometry (ppFEV1, FEF 25 %–75% ) and MBW (LCI 2.5) were observed at 3‐months, and 6‐months post treatment ( p < 0.001). As a group, the lung T1‐MRI findings showed no significant changes despite a trend for improved lung perfusion. However, lung T1‐MRI did show a significant improvement in both 3‐months and 6‐months after starting ETI therapy ( p < 0.03) when evaluating only those subjects with mild‐moderate lung disease (ppFEV1 at baseline.

Conclusions

MBW, spirometry, and lung T1‐MRI are all capable of detecting lung airway and perfusion changes in cwCF 6–11 years of age following the start of ETI therapy. MBW and spirometry assessments were able to detect a sustained improvement in pulmonary function testing regardless of baseline lung status, while lung T1‐MRI was able to detect significant improvements in lung perfusion in patients with more advanced lung disease. These findings, in combination with our prior cross‐sectional findings, suggest that MBW and lung T1‐MRI may provide complementary alternatives to chest CT and can be used to assess disease progression and/or response to therapy.

Subjects

MeSH terms (MEDLINE)

AminophenolsCystic FibrosisLungMagnetic Resonance ImagingQuinolonesChildFemaleHumansMaleBreath TestsDrug CombinationsLongitudinal StudiesSpirometry

Author keywords

T1 mappingchildrencystic fibrosislunglung clearance indexmagnetic resonance imagingmultiple breath washoutpulmonary disease

Substances

AminophenolsDrug CombinationsQuinolones

Authors and institutions

  • Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA.
  • Case Western Reserve University, Cleveland, Ohio, USA.
  • Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Advanced Radiology Services, Grand Rapids, Michigan, USA.
  • Riley Hospital for Children, Indianapolis, Indiana, USA.
  • Rainbow Babies and Children's Hospital, University Hospitals - Cleveland Medical Center, Cleveland, Ohio, USA.

ORCID profiles: Chris A Flask, Madison E Kretzler, Kimberly A McBennett, Clement L Ren

Funding

  • Cystic Fibrosis Foundation, Bethesda, Maryland

Cite

APA

Nasr, S. Z., Flask, C. A., Kretzler, M. E., Slaven, J. E., Joshi, A., Mahani, M. G., Clem, C., Cooper, M., Farr, S., MacAskill, C. J., Gupta, A., Ferrebee, M., McBennett, K. A., & Ren, C. L. (2026). Lung T1‐MRI and Multi‐Breath Washout Detect Longitudinal Changes in Children 6–11 Years Old After Beginning Elexacaftor/Tezacaftor/Ivacaftor (ETI) Therapy. Pediatric Pulmonology, 61(4). https://doi.org/10.1002/ppul.71628

Vancouver

Nasr SZ, Flask CA, Kretzler ME, Slaven JE, Joshi A, Mahani MG, et al. Lung T1‐MRI and Multi‐Breath Washout Detect Longitudinal Changes in Children 6–11 Years Old After Beginning Elexacaftor/Tezacaftor/Ivacaftor (ETI) Therapy. Pediatric Pulmonology. 2026;61(4). doi:10.1002/ppul.71628

BibTeX
@article{Nasr2026,
  author = {Nasr, Samya Z and Flask, Chris A and Kretzler, Madison E and Slaven, James E and Joshi, Aparna and Mahani, Maryam Ghadimi and Clem, Charles and Cooper, Matthew and Farr, Susan and MacAskill, Christina J and Gupta, Amit and Ferrebee, Matthew and McBennett, Kimberly A and Ren, Clement L},
  title = {Lung T1‐MRI and Multi‐Breath Washout Detect Longitudinal Changes in Children 6–11 Years Old After Beginning Elexacaftor/Tezacaftor/Ivacaftor (ETI) Therapy},
  journal = {Pediatric Pulmonology},
  year = {2026},
  volume = {61},
  number = {4},
  doi = {10.1002/ppul.71628}
}
Start for free →